Irritable Bowel Syndrome With Diarrhea — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for irritable bowel syndrome with diarrhea. 43 active patents protecting 2 drugs from 2+ originators. First major cliff: 2028. Daily refresh.

2
Approved drugs
43
Active US patents
60/100
Avg vulnerability
$1.5B
Annual revenue covered

Originators in Irritable Bowel Syndrome With Diarrhea

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AbbVie 26 patents Bausch Health 17 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating irritable bowel syndrome with diarrhea. Each bar = one year. Y-axis scaled to peak year (17 patents).

2
27
8
28
17
29
16
33

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Viberzi
ELUXADOLINE
 AbbVie 26 53 — 2028-07-07
Xifaxan
rifaximin
 Bausch Health 17 66 $1.5B 2027-09-02

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11779571 Xifaxan method of use 83 2029-02-26
11564912 Xifaxan method of use 83 2029-02-26
8193196 Xifaxan method of use 80 2027-09-02
9115091 Viberzi method of use 75 2028-07-07
9364489 Viberzi method of use 75 2028-07-07
9364489 Viberzi method of use 75 2028-07-07
8691860 Viberzi method of use 75 2028-07-07
9789125 Viberzi method of use 75 2028-07-07
8691860 Viberzi method of use 75 2028-07-07
9789125 Viberzi method of use 75 2028-07-07

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7741356 Viberzi composition of matter 10 2029-05-27
7741356 Viberzi composition of matter 10 2029-05-27
8193196 Xifaxan composition of matter 22 2027-09-02
11007179 Viberzi formulation 42 2033-03-14
11160792 Viberzi formulation 42 2033-03-14
10188632 Viberzi formulation 42 2033-03-14
9675587 Viberzi formulation 42 2033-03-14
11090291 Viberzi formulation 42 2033-03-14
11090291 Viberzi formulation 42 2033-03-14
9675587 Viberzi formulation 42 2033-03-14

Related